 The US Food and Drug Administration FDA on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimers disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized in a congressional report ... FDA Approves New Alzheimers Drug Designed to Slow Cognitive... 